Skip to main content

belrestotug

Generic: Belrestotug

belrestotug: developed by 1 company · 5 clinical trials tracked.

belrestotug evidence translation

What we can confirm

What it means

Source-backed records connect belrestotug to ITOS; that link alone does not prove the drug works.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

How could belrestotug → ITOS affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence2 indications · 0 study sponsors

Related indications

Adult cancer patients with advanced solid tumors; studied in combination in first-line non-small cell lung cancer (NSCLC) and first-line advanced or metastatic head and neck squamous cell carcinoma (HNSCC); evaluated in relapsed or refractory multiple myeloma in combination with iberdomide +/- dexamethasoneNeoplasms

Study sponsors

No additional listed-company sponsor is linked.

Development Pipeline (2)
CompanyPhase
iTeos Therapeutics, Inc. (ITOS)
Adult cancer patients with advanced solid tumors; studied in…
Phase 2
iTeos Therapeutics, Inc. (ITOS)
Neoplasms
Phase 3
Clinical Trials (5)

A Randomized, Multicenter, Double-blind, Phase 3 Study to Investigate the Safety and Efficacy of Belrestotug in Combination With Dostarlimab Compared With Placebo in Combination With Pembrolizumab in Participants With Previously Untreated, Unresectable, Locally Advanced or Metastatic PD-L1 Selected Non-small Cell Lung Cancer (GALAXIES Lung-301)

NCT06472076·Phase 3
Active, not recruiting

Primary endpoint: Number of Participants with Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

InterventionalRandomizedquadruple88 targetStarted 2024-06Completion 2027-0850 sites · Argentina, Belgium, Brazil, Bulgaria…GlaxoSmithKline

A Phase 2, Randomized, Open-label, Platform Study Using a Master Protocol to Evaluate Novel Immunotherapy Combinations as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck

NCT06062420·Phase 2
Active, not recruiting

Primary endpoint: Confirmed Objective Response Rate (ORR) compared between Sub studies and Dostarlimab monotherapy

InterventionalRandomizedopen316 targetStarted 2023-11Completion 2027-1250 sites · Argentina, Brazil, Canada, Denmark…GlaxoSmithKline

A Phase 2, Randomized, Open-label, Platform Study Utilizing a Master Protocol to Evaluate Novel Immunotherapy Combinations in Participants With Previously Untreated, Locally Advanced/Metastatic, Programmed Death Ligand 1-Selected Non-Small-Cell Lung Cancer

NCT05565378·Phase 2
Active, not recruiting

Primary endpoint: Number of Participants with Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

InterventionalRandomizedopen351 targetStarted 2022-10Completion 2027-1250 sites · Argentina, Belgium, Brazil, Finland…GlaxoSmithKline

A Phase 1 First-Time-in-Human, Open-Label Study of GSK6097608 Administered as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors

NCT04446351·Phase 1·ITOS
Active, not recruiting

Primary endpoint: Number of participants with dose-limiting toxicities (DLTs)

Interventionalopen107 targetStarted 2020-06Completion 2026-1211 sites · Canada, Japan, South Korea, United StatesGlaxoSmithKline

A Phase II, Randomized, Open-label Platform Trial Utilizing a Master Protocol to Study Novel Regimens Versus Standard of Care Treatment in NSCLC Participants

NCT03739710·Phase 2·ITOS
Completed

Primary endpoint: Number of Participants Randomized Across Sub-studies

InterventionalRandomizedopen175 enrolledStarted 2019-01Completion 2024-0550 sites · Canada, France, Germany, Italy…GlaxoSmithKline

Frequently asked questions

Who is developing belrestotug?

belrestotug is being developed by iTeos Therapeutics, Inc..

How many clinical trials involve belrestotug?

BioSniper tracks 5 clinical trials involving belrestotug.